Abstract 323P
Background
An immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently been discovered, and it demonstrates superior treatment efficacy and improves prognosis over existing chemotherapeutic agents in non-small cell lung cancer. Several studies have demonstrated correlations between computed tomography (CT) imaging features and PD-L1 expression in lung adenocarcinoma (ADC). However, there have been few studies on the association between lung squamous cell carcinoma (SCC) and CT findings. Thus, we aimed to identify the associations between CT findings and PD-L1 expression in SCC and to develop models to predict the expression of PD-L1 in lung SCC using CT.
Methods
This retrospective study included 99 patients diagnosed with SCC and pretreatment CT images and PD-L1 expression assay results. We performed CT feature analysis of the tumors using pretreatment CT images. We then constructed multiple logistic regression models to predict PD-L1 positivity in the total patient group and in 41 advanced-stage (≥ stage IIIB) patients. To identify predictive efficiency, areas under the receiver operating characteristic curves (AUCs) of each model were calculated.
Results
Among the 99 patients, 68 (68.7%) were PD-L1-positive and among the 41 advanced patients, 30 (73.2%) were PD-L1-positive. For the total patient group, the AUC of the ‘total significant features model’ (tumor stage, primary tumor size, pleural nodularity and lung metastasis) was 0.637, and that of the ‘selected feature model’ (pleural nodularity) was 0.556. For advanced-stage patients, the AUC of the selected feature model (primary tumor size, central distribution, pleural nodularity, and pulmonary oligometastases) was 0.882. Among these factors, the presence of pleural nodularity and pulmonary oligometastases had high odds ratios (4.11 and 9.60, respectively).
Conclusions
Our model was able to predict PD-L1 expression in patients with advanced-stage SCC of the lung, and the presence of pleural nodularity and pulmonary oligometastases were notable predictive CT features of PD-L1. A predictive model based on CT features may facilitate non-invasive assessment of PD-L1 expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by a VHS Medical Center Research Grant, Republic of Korea (grant number: VHSMC 21007).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
334P - Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Presenter: Gwo Fuang Ho
Session: Poster viewing 05.
335P - Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Presenter: Hiroshi Yokouchi
Session: Poster viewing 05.
336P - Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Presenter: Dmitrii Shek
Session: Poster viewing 05.
337P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster viewing 05.
338P - Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Presenter: Joe Wei
Session: Poster viewing 05.
339P - Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
Presenter: Charlotte McKay
Session: Poster viewing 05.
341P - Cost-effectiveness analysis of first-line atezolizumab for patients with stage IV non-small cell lung cancer whose tumours have a high-programmed death ligand 1 expression in Thailand
Presenter: Kankamon Kittrongsiri
Session: Poster viewing 05.
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Presenter: Herdee Gloriane Luna
Session: Poster viewing 05.
343P - Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Presenter: Harshitha N.J
Session: Poster viewing 05.